Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03656393
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT03620032
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 257
- Registration Number
- NCT03618550
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 257
- Registration Number
- NCT03456076
- Locations
- 🇷🇺
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺GUZ Regional clinical hospital # 1, Krasnodar, Russian Federation
Chemotherapy and G-CSF for Mobilization
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 137
- Registration Number
- NCT03442673
- Locations
- 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland
Vinorelbine for Recurrent ALCL-2017
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Children's Cancer Group, China
- Target Recruit Count
- 20
- Registration Number
- NCT03443128
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, Shanghai, China
The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03423849
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 100
- Registration Number
- NCT03414658
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 567
- Registration Number
- NCT03402048
- Locations
- 🇮🇹
Ospedale di Faenza, Faenza, Ravenna, Italy
🇮🇹AUSL Rimini-Oncologia Medica Cattolica, Cattolica, Rimini, Italy
🇮🇹AOU Santa Croce e Carle, Cuneo, Italy
Vinorelbine for Recurrent ACLC
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Children's Cancer Group, China
- Target Recruit Count
- 20
- Registration Number
- NCT03397953
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.